BRIEF published on 06/14/2024 at 22:50, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 1 year 9 months ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 1 year 9 months ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
PRESS RELEASE published on 06/06/2024 at 13:00, 1 year 9 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 1 year 9 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
PRESS RELEASE published on 06/04/2024 at 13:00, 1 year 9 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
Published on 03/20/2026 at 03:10, 2 hours 33 minutes ago Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 5 hours 23 minutes ago Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A
Published on 03/20/2026 at 00:20, 5 hours 23 minutes ago Reeflex Solutions Inc. Announces Revocation of Management Cease Trade Order
Published on 03/19/2026 at 21:16, 8 hours 27 minutes ago Unusual Machines, Inc. Announces Proposed Public Offering
Published on 03/19/2026 at 14:20, 15 hours 23 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/20/2026 at 03:05, 2 hours 37 minutes ago HEROAD Unleashes a New Era of Gaming: Professional-Grade Gear Meets Unbeatable Value
Published on 03/19/2026 at 23:48, 5 hours 54 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C daily buy back notice
Published on 03/19/2026 at 22:55, 6 hours 47 minutes ago Baristas behind millions of cups of coffee compete globally
Published on 03/19/2026 at 22:48, 6 hours 54 minutes ago EQS-Adhoc: Forecast for the 2026 financial year
Published on 03/19/2026 at 18:00, 11 hours 43 minutes ago Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 08:45, 20 hours 58 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 22 hours 43 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 22 hours 43 minutes ago 2025 Annual results and new strategic signature
